,Key,Value
0,identifier, N/A
1,collection_site, N/A
2,specimen_type, N/A
3,name, John Doe
4,contact_info, N/A
5,birth_date, N/A
6,gender, Male
7,zip_code, N/A
8,us_core_race, Caucasian
9,us_core_birth_sex, Male
10,us_core_ethnicity, N/A
11,death_date, N/A
12,evidence_type, Stage IV
13,tumor_identifier, N/A
14,body_location, Lung
15,longest_dimension, N/A
16,other_dimension, N/A
17,stage_type, Stage IV
18,staging_method, ECOG Performance Status
19,leukemia_binet_stage, N/A
20,leukemia_rai_stage, N/A
21,gynecologic_figo_stage, N/A
22,lymphoma_stage, N/A
23,melanoma_breslow_stage, N/A
24,melanoma_clark_level, N/A
25,myeloma_iss_stage, N/A
26,myeloma_riss_stage, N/A
27,prostate_gleason_stage, N/A
28,asserted_date," January 10, 2023"
29,histology/morphology, Non-Small Cell Lung Cancer (NSCLC)
30,body_site, Lung
31,secondary_cancer_condition, N/A
32,test_type," EGFR mutation, TP53 mutation, KRAS gene"
33,result_value, N/A
34,medication," EGFR Tyrosine Kinase Inhibitors (TKIs), pembrolizumab, cisplatin, gemcitabine"
35,reason, N/A
36,procedure_intent, N/A
37,status_reason, N/A
38,medicaiton, N/A
39,status_reason, N/A
40,procedure_code, N/A
41,number_of_sessions, N/A
42,modality/technique, N/A
43,radiotherapy_volumn, N/A
44,history_of_metastatic_cancer, N/A
45,comorbidities, N/A
46,remonic_variant, N/A
47,variation_code, N/A
48,genomic_hgvs, N/A
49,coding_change_type, N/A
50,protein_hgvs, N/A
51,amino_acid_change_type, N/A
52,molucular_consequence, N/A
53,cytogen_nomemclature, N/A
54,gene_studied," EGFR, TP53, KRAS"
55,genomic_source_class, N/A
56,copy_number, N/A
57,allelic_frequency, N/A
58,allelic_state, N/A
59,cytogenetic_location, N/A
60,gene_mutations, N/A
61,coordinate_system, N/A
62,ranges_examined, N/A
63,region_description, N/A
64,reference_sequence, N/A
